Shareholders with losses of $100,000 or more are encouraged to contact the firm. LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Neogen Corporation...
Related Questions
How might the lawsuit affect Neogen's stock price in the short and long term?
What is the estimated potential liability or settlement amount for the class action?
Which specific allegations are being made in the securities fraud claim?
How many shareholders qualify to lead the lawsuit and what proportion of total shareholders does that represent?
What is the timeline for the litigation and any upcoming court dates?
How might the lawsuit affect Neogen’s cash flow, debt covenants, or credit ratings?
What precedent is there for similar class actions in the biotech/food safety sector?
Are there any other pending regulatory or legal issues that could compound the risk?
Could this lawsuit lead to a corporate governance or management change at Neogen?
What impact could this have on Neogen's relationships with customers, suppliers, and partners?
How might the lawsuit influence analyst ratings or institutional investor sentiment?
What risk mitigation strategies should be considered in portfolio allocation?
Could the lawsuit trigger a proxy fight or board reorganization?
What are the potential implications for the company’s ongoing R&D and product pipeline?
How might this affect Neogen's ability to raise capital or issue new equity or debt?